Abstract. Gemcitabine (GEM) is the standard treatment for advanced/metastatic pancreatic cancer. However, there is a substantial subset of patients in whom the efficacy of GEM, when used as a single agent, is inadequate. Recently, the 5-fluorouracil (5-FU) prodrugs capecitabine and S-1 have been used as an alternative, either alone or in combination with GEM. The aim of the present study was to investigate the expression pattern of genes that render pancreatic cancer cells sensitive to GEM and 5-FU, and to identify markers for individualized chemotherapy, even in patients who have developed resistance. We investigated the correlation between the expression of genes associated with the metabolism of GEM and 5-FU, and sensitivity to these drugs in 15 human pancreatic cancer cell lines. We also established GEM-and 5-FU-resistant pancreatic cancer cell lines to investigate changes in the expression levels of these genes and the effects of one drug on cells resistant to the other. We found no correlation between pancreatic cancer cell sensitivity to either GEM-or 5-FU. GEM-resistant cells did not become resistant to 5-FU and vice versa. High expression of RRM1 (P=0.048) and TS x DPD (P= 0.035) correlated significantly with sensitivity to GEM and 5-FU, respectively. 5-FU-resistant cells expressed significantly higher levels of TP than parental cells (P<0.05). In conclusion, pancreatic cancer cells showed no crossresistance to GEM and 5-FU. Quantitative analyses of RRM1, TP, DPD and TS mRNA levels in pancreatic cancer cells may be useful for predicting their sensitivity to GEM and 5-FU.
Introduction
The prognosis for patients with pancreatic cancer is extremely poor. The tumor is extremely aggressive and early detection is difficult due to the lack of early disease-specific signs and symptoms. Only 10-20% of patients with pancreatic cancer are candidates for curative resection (1, 2) and, even if surgery is performed, the post-operative 5-year survival rate is only 15-25% due to the high incidence of postoperative recurrence (1, 3, 4) . Gemcitabine (difluorodeoxycitidine, dFdC; GEM) is the standard treatment for advanced/metastatic pancreatic cancer based on a landmark trial comparing its effects with those of fluorouracil (FU) (5) . However, the clinical benefit of GEM as a single agent is inadequate, as indicated by the median survival time of only 5.7-7.2 months and a low objective response rate (5) (6) (7) (8) (9) . Thus, there is a pressing need to develop new treatment strategies. Recently, a phase III trial for advanced pancreatic cancer showed a significant increase in both overall survival (OS) and progression-free survival (PFS) after treatment with erlotinib plus GEM compared with GEM alone. Although these results were statistically significant, the absolute benefit of OS was modest (only 2 weeks) (9) .
GEM is a deoxycytidine analog that has significant singleagent activity against a number of malignancies, including pancreatic cancer (10, 11) . GEM is transported into cells via the human equilibrative nucleoside transporter-1 (hENT1) (12) and must be phosphorylated by deoxycytidine kinase (dCK) to be activated. The phosphorylated forms of GEM inhibit DNA synthesis through its incorporation into DNA leading to masked chain termination, and by inhibiting the enzyme ribonucleotide reductase (RR) (13, 14) . In addition, the deoxyribonucleotide and ribonucleotide pools, both essential for DNA repair, are seriously depleted by the phosphorylated forms (15) . Conversely, GEM is inactivated by cytidine deaminase (CDA) (16) . We, and other investigators, showed that the expressions of hENT1, dCK, the RR subunits M1 (RRM1) and M2 (RRM2), and the genes that encode them were, at least partially, correlated with sensitivity to GEM (17) (18) (19) (20) (21) (22) (23) (24) (25) .
Recently, the orally administered fluoropyrimidine prodrugs, capecitabine and S-1, have been used as alternative Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil (7) . Capecitabine is metabolized to 5-FU via a three-step enzymatic process, the final step being catalyzed by thymidine phosphorylase (TP) (26) . Meanwhile, a late phase II study using S-1 to treat metastatic pancreatic cancer showed promising results, with a 37.5% response rate and a median OS of 9.2 months (27) . S-1 consists of tegafur (FT; a prodrug of 5-FU) and two biochemical modulators, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) (28) , which improve the tumor-selective toxicity of 5-FU. CDHP is a competitive inhibitor of dihydropyrimidine dehydrogenase (DPD), which rapidly catabolizes 5-FU and maintains efficacious 5-FU concentrations in the plasma and tumor tissues (29) . Oxo decreases phosphorylation of 5-FU within the gastrointestinal tract by competitively inhibiting orotate phosphoribosyltransferase (OPRT), thereby reducing the serious gastrointestinal toxicity associated with 5-FU (30) . Finally, in both agents, 5-FU interacts with its pharmacological target, thymidylate synthase (TS) and inhibits DNA synthesis and repair. Increasing evidence suggests that the expression levels of TP, DPD, OPRT and TS (along with the genes that encode them) predict sensitivity to 5-FU or its prodrugs (26, (29) (30) (31) (32) . Although GEM and 5-FU prodrugs are effective against advanced pancreatic cancer when used as single agents, there is a substantial subset of patients in whom the efficacy is limited or inadequate. Also, few studies have investigated whether these agents are effective in patients who have developed resistance to other agents. Recent studies show that altered gene expression can, at least in part, explain the efficacy of cytotoxic agents (19, 33) . Therefore, in the present study, we investigated the correlation between the expression of genes associated with the metabolism of GEM and 5-FU and cancer cell sensitivity to the drugs using 15 human pancreatic cancer cell lines. Furthermore, we established pancreatic cancer cell lines that are resistant to each agent to investigate the effects of one drug on pancreatic cancer cell lines that were resistant to the other. We also analyzed the expression levels of genes related to the transport and metabolism of GEM and 5-FU to clarify the underlying mechanisms involved in drug-resistance.
Materials and methods

Cell lines and establishment of GEM or 5-FU-resistant cells.
The following 15 human pancreatic cancer cell lines were used in this study: BxPC-3, Capan-1, Capan-2, CFPAC1, Hs766T, SW1990 (American Type Culture Collection, Manassas, Virginia, USA), AsPC-1, H48N, KP-1N, KP-2, KP-3, Panc-1, SUIT-2 (generously provided by Dr H. Iguchi (National Shikoku Cancer Center, Matsuyama, Japan), MIA PaCa-2 (Japanese Cancer Resources Bank, Tokyo, Japan) and NOR-P1; established in our laboratory (34) . Cells were main tained as previously described (35) . Cells resistant to GEM (Wako, Osaka, Japan) or 5-FU (Kyowa Hakko Kogyo, Tokyo, Japan) were generated by exposure to gradually increasing concentrations of each drug as previously described (23) . The final concentrations of GEM and 5-FU were 200 nM and 2 µM, respectively. Both agents were dissolved in phosphate-buffered saline and added to the culture medium [Dulbecco's modified Eagle's medium, DMEM; Sigma Chemical Co., St. Louis, MO, USA; supplemented with 10% fetal bovine serum (FBS), streptomycin (100 µg/ml) and penicillin (100 U/ml)].
Propidium iodide (PI) assay. To calculate the 50% inhibitory concentration (IC 50 ) for each cell line when exposed to GEM or 5-FU, cells were seeded in 24-well plates (BectonDickinson Labware, Bedford, MA, USA) at a density of 2x10 4 per well, using cell numbers previously counted using a particle distri bution analyzer (CDA 500; Sysmex, Kobe, Japan). Several different concentrations of GEM or 5-FU were added to the cells 24 h after seeding. Cell populations were evaluated by measuring the fluorescence intensity of PI after a further incubation for 72 h, as previously described (19, 23) .
Quantitative one-step real-time reverse transcriptionpolymerase chain reaction (qRT-PCR). Total RNA was extracted from cultured cells using a High Pure RNA isolation kit (Roche, Mannheim, Germany) with DNase (Roche) treatment according to the manufacturer's instructions. qRT-PCR was performed for 40 cycles of 15 sec at 95˚C and 1 min at 55˚C using a Chromo4 real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA, USA) and a QuantiTect SYBR-Green reverse transcription-PCR kit (Qiagen) according to the manufacturer's instructions (36) . Specific primers were designed (Table I) , and BLAST searches were performed to ensure the primer specificities. The levels of hENT1, dCK, RRM1, RRM2, TP, OPRT and TS mRNA were calculated from standard curves constructed using total RNA from Capan-1 cells. The levels of CDA and DPD m R NA were calculated from standard curves constructed using total RNA from SUIT-2 cells. The level of each mRNA was normalized to that of 18S rRNA.
Statistical analysis. Statistical analyses and graphical presentations were done using JMP 8.0 software (SAS Institute, Cary, NC, USA). Values were expressed as the mean ± SD. Comparisons between two groups were done using Student's t-test. The correlation between two groups was analyzed using Spearman's rank-correlation test. Statistical significance was defined as P<0.05.
Results
Correlation between GEM or 5-FU IC 50 values and gene expression levels associated with drug metabolism.
To investigate the chemosensitivity of pancreatic cancer cells to GEM and 5-FU, the IC 50 values after exposure were calculated for all 15 cell lines (Table II) We next quantified the expression levels of genes involved in the cellular uptake and metabolism of GEM and 5-FU (Tables III and IV) Relative mRNA expression levels normalized to those of 18S rRNA Table IV . Relative expression levels of mRNAs associated with 5-FU metabolism in the pancreatic cancer cell lines.
Relative mRNA expression levels normalized to those of 18S rRNA catalyze another process that yields 5'-fluoro-2'-deoxyuridine-5'-monophosphate, which forms a stable ternary complex with TS to block DNA synthesis and repair (40) , there was no significant correlation between the IC 50 values for 5-FU and the expression levels of RRM1 or RRM2.
Establishment of GEM-resistant pancreatic cancer cells.
To investigate the altered expression levels of GEM transport-and metabolism-related genes in GEM-resistant cells, the GEMresistant pancreatic cancer cells SUIT-2-GR and Capan-1-GR were generated from the parental cell lines (SUIT-2-parent and Capan-1-parent). The GEM IC 50 values for both of these GEM-resistant cell lines were significantly higher than those of the parental cells (Table VII , Fig. 2A and B; P<0.001).
Although SUIT-2-GR cells showed significantly decreased expression levels of hENT1, Capan-1-GR cells showed a significant increase in expression (Fig. 2C) . The expression levels of dCK significantly decreased (Fig. 2D ) and those of RRM1 and RRM2 significantly increased in both of the GEM-resistant cell lines ( Fig. 2E and F) . The expression level of CDA in SUIT-2-GR cells was significantly higher than that in SUIT-2-parent cells, whereas expressions in the Capan-1-parent and Capan-1-GR cells were very low (and not significantly different) (Fig. 2G) . The data regarding the expression levels of RRM1 in GEM-resistant cells were (20) and increased expression of CDA (16) , which were only observed in SUIT-2-GR cells, is associated with the development of GEM-resistance, our results from both of the GEM-resistant cells indicated that lower dCK, expression, coupled with higher RRM1 and RRM2 expressions, are important factors for developing resistance to this agent.
Establishment of 5-FU-resistant pancreatic cancer cells.
We generated 5-FU-resistant SUIT-2 (SUIT-2-FR) and Capan-1 (Capan-1-FR) cells by exposure to gradually increasing concentrations of 5-FU. The 5-FU IC 50 values for both of these resistant cell lines were significantly higher than those of the parental cell lines (Table VII and Fig. 3A and B; P<0.001). As outlined above for the GEM-resistance cells, we measured the expression of genes associated with 5-FU metabolism ( Fig. 3C-F) . The expression levels of TP, DPD, OPRT and TS in SUIT-2-FR cells were significantly higher than those in the parental cells (Fig. 3C-F) . Meanwhile, Capan-1-FR cells showed a significant increase in TP expression compared with Capan-1-parent cells (Fig. 3C) . Although the level of DPD expression in Capan-1-FR cells was significantly higher than that in Capan-1-parent cells, it was still extremely low ( Fig. 3D ) compared with that in the SUIT-2 cell lines. The expression levels of OPRT and TS in both of the Capan-1 cell lines were almost the same (Fig. 3E and F) . Although previous reports showed that increased expressions of OPRT and TS, which we observed only in SUIT-2-FR cells, were associated with resistance to 5-FU and its prodrugs (32, 38, 40) , our results from both of the 5-FU-resistant cell lines indicated that increased expressions of TP and DPD are important for developing 5-FU-resistance. We also calculated the TS x DPD expression level in these cell lines and found that both 5-FU-resistant cell lines showed significantly higher levels of combined expression than the parental cells, although expression levels in Capan-1 cells were lower than those in SUIT-2 cells (Fig. 3G) .
GEM-sensitivity of 5-FU-resistant pancreatic cancer cells.
To investigate whether there was any cross-resistance to 5-FU and GEM, we examined the sensitivity of 5-FU-resistant cells to GEM. The GEM IC 50 value of SUIT-2-FR cells was slightly (but significantly) lower than that of the parental cells (Fig. 4A and Table IV ; P<0.001); however, there was no significant difference in GEM-sensitivity between Capan-1-FR cells and Capan-1-parent cells (Fig. 4B ). This suggests that the acquisition of 5-FU-resistance had no effect on GEM-sensitivity.
To assess the effects of 5-FU-resistance on the expression levels of genes related to GEM transport and metabolism, we measured the expression levels of these genes in 5-FU-resistant and parental cells. SUIT-2-FR cells expressed significantly higher levels of hENT1, dCK, RRM1 and RRM2, and significantly lower levels of CDA, than the parental cells (Fig. 4C-G) . Meanwhile, Capan-1-FR cells showed no significant changes in expression levels of hENT1, RRM1 and RRM2 compared with the parental cells (Fig. 4C, E and F) , although they did show significantly decreased expressions of dCK and CDA (Fig. 4D and G) . Despite significantly increased expressions of RRM1 and RRM2, SUIT-2-FR cells did not become resistant to GEM. These results suggest that there may be a substantial number of patinets who become sensitive to GEM (via increased expressions of dCK and hENT1) after developing resistance to 5-FU.
5-FU sensitivity of GEM-resistant pancreatic cancer cells.
We also investigated the sensitivity to 5-FU of GEM-resistant cells and found that GEM-resistant cells had similar levels of 5-FU-sensitivity to the parental cells ( Fig. 5A and B) . These data suggest that GEM-resistance did not affect 5-FUsensitivity.
Similarly, we measured the expression levels of the genes related to 5-FU metabolism in GEM-resistant cell lines (Fig. 5C-F) . Although there was no significant change in the expression level of TP, the levels of OPRT, TS and TS x DPD expression were significantly higher in both of the GEMresistant cell lines than in parental cells (Fig. 5C, E-G) . SUIT-2-GR cells showed significantly higher level of DPD expression than the SUIT-2-parent cells, whereas the expression levels in Capan-1-GR and Capan-1-parent cells were too low to compare (Fig. 5D) . Although GEM-resistant cells showed significant increases in DPD, OPRT, TS and TS x DPD expression levels (as observed in 5-FU-resistant cells) (Fig. 3C-G) , they did not become resistant to 5-FU. This suggests that increased expression of TP may be essential for the development of 5-FU-resistance in both cell lines.
Discussion
Although GEM-based chemotherapy is still the standard palliative chemotherapy for pancreatic cancer (5, 11) , the efficacy of GEM as a single agent is limited, and clinicians are often torn when faced with GEM-refractory patients. To improve the prognosis of patients with pancreatic cancer, much effort has been put into developing other effective firstand second-line chemotherapy regimens such as 5-FU prodrugs, used alone or in combination with GEM; however, their therapeutic effects are modest or disappointing. Therefore, individualized chemotherapy based on the gene expression profiles of the individual's own cancer tissues would be a helpful strategy for selecting those patients that are likely to respond to treatment (20, 33) . Many studies of the mechanisms of GEM and 5-FU metabolism have suggested that certain genes/proteins are associated with sensitivity to these drugs (12) (13) (14) (15) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) 39, 40) . However, to our knowledge, there is no study evaluating acquired cross-resistance between GEM and 5-FU and its correlation with gene expression.
In the present study, we analyzed the IC 50 values for GEM and 5-FU in 15 pancreatic cancer cell lines and found no correlation between sensitivity to either drug. Moreover, we evaluated sensitivity to these agents using pancreatic cancer cell lines resistant to either GEM or 5-FU and found that these GEM-or 5-FU-resistant cells acquired no cross-resistance to the other agent. These data suggest that first line chemotherapy using either GEM-or 5-FU may not promote resistance to the other drug and confirm that combination therapy, or secondline chemotherapy using one or other of the drugs, may be a useful strategy for treating pancreatic cancer. Notably, SUIT-2-FR cells showed slightly (but significantly) higher sensitivity to GEM than parental cells. However, recent clinical studies have not shown striking results with second-line chemotherapy (41) (42) (43) ; therefore, further investigation is needed to select the best agents for first-or second-line chemotherapy for pancreatic cancer.
To evaluate whether any changes occurred in cells that developed resistance to GEM or 5-FU, we also analyzed the expression levels of the genes associated with transport and metabolism in 15 pancreatic cancer cell lines and GEM-or 5-FU resistant cells. Regarding GEM, the present data suggest that lower expression of dCK, coupled with higher expressions of RRM1 and RRM2 may be important factors for developing the resistance to this drug. Akita et al (44) demonstrated that only patients with low levels of RRM1 expression derive significant benefit from GEM in terms of preventing disease recurrence. Therefore, RRM1 expression may contribute to GEM-resistance in pancreatic cancer. However, SUIT-2-FR cells did not become resistant to GEM, despite increased RRM1 expression levels, suggesting that quantification of several genes and a combined evaluation of the results may be needed if individualized chemotherapy based on gene expression profiles is to be used in a clinical setting.
The data regarding 5-FU-resistant cells suggest that higher TP, DPD and TS x DPD expressions may be important factors for developing the resistance to this drug. There was no significant change in 5-FU-sensitivity in GEM-resistant cells expressing higher levels of DPD, OPRT, TS and TS x DPD, suggesting that increased expression levels of TP may be essential for the development of 5-FU-resistance. Increased TP expression was initially reported to be correlated with increased sensitivity to 5-FU, possibly due to increased synthesis of 2'-deoxy-5'-fluorouridine (FUDR) (45) . However, higher TP expression was also reported to correlate with a poor response to 5-FU-based treatment and shorter survival times in colorectal (45) and pancreatic cancer (39) patients, although there are conflicting results (46) . TP is identical to platelet-derived endothelial cell growth factor (PD-ECGF) in terms of its pro-angiogenic activity; therefore, the activity of this enzyme is used as a prognostic indicator (47) . Conversely, TP is also an enzyme that metabolizes the 5-FU prodrug, cape citabine (N4-pentoxycarbonyl-5'-5-fluorocytidine). This is an attractive novel fluoropyrimidine analogue with great clinical potential. It is metabolized in the liver and tumor tissues to 5'-deoxy-5-fluorouridine (5'-DFUR) by CDA. 5'-DFUR is then converted to 5-FU by TP (26, 46) . Because TP is highly expressed in tumor tissues relative to host cells, capecitabine can be selectively activated in tumor tissues, suggesting that TP may contribute to capecitabine sensitivity (26, 31) . Additio nally, CDA is also associated with GEM-resistance due to its ability to inactivate GEM (48) . Therefore, capecitabine may be a potent drug for treating GEM-resistant patients showing high CDA expression, or for 5-FU-resistant patients showing high TP expression. However, further studies are needed to elucidate the correlation between capecitabine-sensitivity and CDA and/or TP expression.
In conclusion, we found no cross-resistance between GEM and 5-FU, even in pancreatic cancer cell lines that developed resistance to the other drug. These results suggest that it may be possible to use either of these drugs as second-line chemotherapy in patients with pancreatic cancer that has developed resistance to one of these agents. In addition, quantitative analyses of RRM1, TP, DPD and TS may be a potent strategy for developing individualized chemo-therapeutic regimens.
